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ABSTRACT  
OBJECTIVE  
The objective of this selective EBM review is to determine whether the Chinese herbal 
supplement, Ningdong granule, is a safe and effective alternative to haloperidol for the treatment 
of tic symptoms in pediatric patients with Tourette Syndrome. 
STUDY DESIGN  
Systematic review of three randomized controlled trials published in 2009, 2010, and 2012.  
DATA SOURCES  
Three randomized controlled trials were obtained using PubMed.  
OUTCOMES MEASURED  
Efficacy of Ningdong granule (NDG) as compared to control groups based on decrease in tic 
severity and frequency as reported by Yale Global Tic Severity Scale as well as safety, as 
evidenced by prevalence of adverse drug reactions (ADRs) as compared to control groups. 
RESULTS  
Li et al. (2009), Wang et al. (2012), and Zhao et al. (2010) all demonstrated improvement in a 
majority of the subjects’ tic symptoms while decreasing ADR’s from treatment with Ningdong 
granule compared to haloperidol. 
CONCLUSION  
Evidence to support the efficacy of Ningdong granule to safely treat tic symptoms in pediatric 
Tourette Syndrome patients is strong now, due to a relevant subject population, and consistent 
standard of measurement.  The data strongly supports the efficacy of Ningdong granule as an 
alternative method of treating tic symptoms in pediatric patients suffering from Tourette 
Syndrome.  
KEY WORDS 
Tourette and alternative therapy and Ningdong 
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INTRODUCTION 
Tourette Syndrome is a neuromuscular disorder, onset early in childhood, that causes 
uncontrolled vocal and motor tics ranging from mild to severe.1,2,3,4  While the exact number of 
children with Tourette Syndrome is unknown, a CDC study has shown that it affects up to 1 in 
every 360 children.4  DSM diagnosis requires two motor tics and at least one vocal tic feature 
occurring for at least a year, prior to age 18 that cannot be attributed to some other medical 
condition or medical treatment; the diagnosis is made at an average age of 7.4 The disorder often 
lasts into early adulthood (5-18 years old) and often attenuates by the time the child reaches 
adulthood.4 The exact etiology of Gilles de la Tourette Syndrome (TS) is unknown, however it is 
believed that there are multiple complex genetic, environmental and developmental factors that 
all contribute to the frequency and severity of tic symptoms in patients.4,5  Symptoms in patients 
can be socially, educationally and interpersonally impairing, thus leading to treatment for co-
morbid conditions as well.3  However, in some patients tics can be life threatening, as in 
malignant Tourette Syndrome, or can last throughout their lives.1  This systematic review 
attempts to determine whether or not the Chinese herbal supplement, Ningdong granule (NDG), 
is a safe and effective alternative to haloperidol for treating tic symptoms in pediatric patients.  
This paper evaluates three randomized control trials (RCT), taking place in China, comparing 
Ningdong granule versus haloperidol, Ningdong granule with haloperidol, and placebo alone.  
In the United States, no solid answer as to how many children or adolescents are affected, 
nor how many healthcare dollars are spent on TS because in many cases there are co-morbid 
obsessive compulsive or ADHD diagnoses that are more often treated and insurance billed for.5  
While the CDC estimates 1 in 360 children have TS, it is also thought the actual prevalence may 
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be twice that based on other studies.5   For cost, TS has been lumped into the $267 billion in 
annual mental health costs for mental disorders in children.5  Also, there is no one treatment to 
track for TS as there are multiple medications used, as well as behavioral interventions like 
Cognitive Behavioral Intervention for Tic therapy (CBIT).  The exact number of office visits for 
TS is ambiguous for the same reasons.   
While the exact cause of TS is not known, it seems to have a strong genetic link affecting 
mainly non-Hispanic white males with various biological, mental and environmental factors 
being identified as risk factors.4  86% of Tourette Syndrome diagnoses include a comorbid 
diagnosis of obsessive compulsive disorder (OCD) or attention defecit hyperactivity disorder 
(ADHD).6  The gene link appears to be dominant with 50% of offspring exhibiting the trait and 
males in general are 3 times more likely to exhibit symptoms of TS than females.6 
 It appears that the attenuation of dopamine receptors calms tic symptoms and therefore, 
conventionally, traditional antipsychotic medications that work on DA such as haloperidol are 
used in the management of symptoms in Tourette Syndrome.7  It is known that these medications 
can cause sometimes severe side effects such as extra pyramidal symptoms, akathisia, QT 
prolongation, sedation and weight gain; for these reasons patients often discontinue their 
use.1,2,3,7  Newer methods of treatment include habit reversal therapy, CBIT, psychotherapy, 
acupuncture and herbal medicine.1,2,3  
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether the Chinese herbal 
supplement, Ningdong granule, is a safe and effective alternative to haloperidol for the treatment 
of tic symptoms in pediatric patients with Tourette Syndrome. 
METHODS 
 This systematic review consists of three randomized controlled trials which meet the 
specific requirements for measuring efficacy and safety of Ningdong granule (NDG) in addition 
or compared to haloperidol or placebo alone.  The first randomized control trial was a 3 month, 
two group, double-blind study comparing the decrease in tic severity and ADRs of Ningdong 
granule plus haloperidol to haloperidol alone.  Both NDG/haloperidol and haloperidol were used 
at therapeutic doses.  The second randomized control trial was an 8-week, three group, double-
blind study that compared the decrease in tic severity and ADRs of NDG to NDG + haloperidol 
to haloperidol and placebo alone. The third trial was an 8-week randomized, double blind control 
trial comparing NDG to placebo. The study population of all three trials consisted of children or 
adolescents at or under the age of 18 and who were clinically diagnosed and met the DSM-IV 
criteria for Tourette Syndrome.  The populations excluded from these studies were patients over 
the age of 18 years old, had comorbid conditions requiring medication, history of recent or 
current drug abuse, or had tics that could be accounted for by other medical conditions. 
 Keywords used in the research for these studies were Tourette and alternative therapy and 
Ningdong.  All articles used in this research were peer-reviewed journals and were found via 
PubMed.  The articles were published in English and in Chinese.  To be selected, the articles 
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researched had to meet several inclusion criteria including: being relevant to the clinical question 
proposed, published in 2001 or later, must have been primary research and addressed patient 
oriented outcomes (POEM).  Criteria for exclusion included articles published prior to the year 
2001, articles that were not primary research in nature (other reviews) or if they focused on 
disease oriented outcomes (DOE).  Statistics used in the articles include p-values, NNT, NNH, 
RRI, RBI, and ABI.  Table 1 below displays the demographics and characteristics of the studies 
that were reviewed and used. 
Table 1:  Demographics & characteristics of included studies 
Study Type #Pts Age 
(yrs.) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Li1 
(2009) 
Double 
Blind 
RCT 
60 <18 Pediatric pts 
dx with TS 
- > 18 years                 
- not matching the 
standard of inclusion  
- habitual spasm          
- complicated with 
other ds in an 
unstable state 
requiring other 
medications 
0 Haloperidol in 
combination with 
dosage-form of 
NDG, 6 g in each 
packet, medicated by 
dissolving in boiled 
water for oral intake 
BID, at the dose of 3 
g each time for 
children younger 
than 6 years, 6 g for 
those between 7-11 
years and 9 g for 
those older than 12 
years.  
Wang2 
(2012) 
Double 
Blind 
RCT 
120 6-18 Pediatric pts 
dx with TS 
- pts who took TS 
medications within 6 
mos. of study  
- pts who had hx of 
seizures, CVD, 
organic brain d/o 
- current abuse or 
dependence on drugs 
w/in 6 mos. 
3 NDG group assigned 
to receive NDG 5 
mg/kg/day and one 
placebo similar in 
appearance and taste 
to Haloperidol for 8 
weeks.  
Zhao3 
(2010) 
Double 
Blind 
RCT 
68 7-18 Pediatric pts 
dx with TS 
- intelligence 
quotient (IQ) < 70 
per the Wechsler 
4 Subjects received 
either an oral dose of 
1 g/kg per day (36 
g/day max) of NDG 
Russell, Efficacy of Ningdong Granule 
 
  
5 
Intelligence Scale for 
Children;19  
- tic syndromes 
caused by other ds 
- dysfunction of the 
liver, kidney or other 
organs 
- a motor or phonic 
tic score < 10 on the 
Chinese Yale Global 
Tic Severity Scale 
(YGTSS) 
powder or placebo 
formulated to look 
identical to the NDG 
to ensure double 
blinding the 
medication being 
administered.  
 
 
OUTCOMES MEASURED 
 All studies used measured the desired outcomes of tic severity by diminution rate of Yale 
Global Tic Severity Scores (YGTSS) and safety of the drug by way of ADR prevalence.  
Participants were given the questionnaires for tic severity prior to the study, immediately after 
the study and in the first study, long term results were measured at variable time intervals after 
the study. In all studies, safety was measured by recording existence of adverse drug reactions 
(ADRs) during treatment in all groups.  In the Li study, tic severity was recorded at baseline, 
immediately after treatment and then at 6 months for long term efficacy; safety was measured in 
ADRs reported and observed vs. control at each interval.  In the Wang study, tic severity was 
assessed at baseline and every two weeks thereafter until study completion at week 8; safety was 
measured by reported and observed ADRs at any time during the study.  In the Zhao study, tic 
severity was measured at baseline and after 4 and 8 weeks of treatment; safety was measured by 
reported and observed ADRs at any time during the study.   
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RESULTS 
 In all three randomly controlled trials, the efficacy and safety of Ningdong granule is 
compared to placebo or haloperidol.  In the Li study, a total of 60 patients entered the study and 
all patients completed the study.  The exclusion parameters for this study included patients who 
were older than 18, did not match the DSM-IV diagnosis for Tourette Syndrome, had habitual 
spasm, or had comorbid disease in an unstable state requiring medication.  The patients were all 
pediatric patients with tic severity at baseline ranging from mild to severe, including both males 
and females in proper proportion.  The mean age of patients was 9.59 years.1 Patients were 
randomized into two groups by randomizing digital table method where n=30 in the control and 
n=60 in the treated group.  Ningdong granule used in this study was Shanghai Xinyi Jiufu 
Pharmaceutical Co. Ltd., batch No. 061210. Group 2 control was treated with haloperidol alone 
at 0.5mg twice per day, titrating to therapeutic doses for each individual. The treated Group 1 
was given haloperidol in the same fashion, but supplemented with 3g/dose twice daily for 
children 6 years, 6g/dose for ages 7-11 and 9g/dose for 12 years of age.  In Group 1 the 
clinical efficacy was found to be markedly effective in 36 (60.0%), effective in 21 and 
ineffective in 3, with a total effective rate of 95.0%.  For the 30 patients in Group 2, data results 
were 9 (30.0%), 13, 8, and 73.3%, respectively. Comparing the markedly effective rate and the 
total effective rate between the groups showed significant differences (P<0.01, Table 2). For 
ADRs in Group 1, drowsiness n=3, lassitude n=2 and poor appetite n=3, the overall ADR rate 
was 13.3%, while in Group 2, drowsiness n=4, constipation n=1, lassitude n=3, poor appetite 
n=1 and akathisia n=2, with an overall ADR rate of 36.7%. There was statistical significance for 
ADRs shown (χ
2
=6.54, P<0.05).  This study was double blind and there were no limitations to 
this study. 
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Table 2.  Li Study: Comparison YGTSS Score, NDG + Haloperidol vs. Haloperidol 
Group Case Markedly Effective Effective Ineffective Total Effective 
Treated 1 60 36 (60.0*) 21 (35.0) 3 (5.0*) 57 (95.0*) 
Control 2 30 9 (30.0) 13 (43.3) 8 (26.7) 22 (73.3) 
2  7.20 2.63 6.85 6.85 
Note: *P<0.01 when compared with control group 
 In the Wang study, 120 patients from Provincial Hospital between the ages of 6-18 with 
TS were recruited for the study.  3 patients did not submit reports for ADRs, 2 in the placebo 
group and 1 in the NDG only group.  Exclusion parameters included patients who took TS 
medications within 6 months of the study, patients who had history of seizures, cardiovascular 
disease, organic brain disorders and those who currently, or within the last 6 months, abused or 
were dependent on drugs.  The study was done by using a digital random table generator to 
randomly assign patients to 4 equal groups (n=30) with Control receiving 2 placebo pills, NDG 
receiving Ningdong granule and a placebo, haloperidol receiving haloperidol and placebo and 
the Ningdong + haloperidol receiving both drugs.  The NDG used was No. 20090412, 999 Co. 
Ltd., Shenzhen, China.  The mean age of patients was 10.2 years old and there was no significant 
difference in weight, age or gender of the groups.  Patients in the placebo controlled group had 
no significant change in YGTSS total tic score, at each time point when compared to baseline (P 
> 0.05). However, two weeks into the study, patients being treated in the three other groups 
showed a significant reduction in total YGTSS scores, thus lower tic severity (p < 0.05), with the 
NDG + Hal group the most significantly reduced (p < 0.01) (Table 3).  While no serious side 
effects were reported overall, patients experiencing sedation, extrapyramidal symptoms, QT 
prolongation and anxiety for NDG vs. haloperidol were found to be significantly less (p<0.05) 
Russell, Efficacy of Ningdong Granule 
 
  
8 
(Table 4).  This study had one limitation for this in that efficacy was assessed over the short 
term. 
Table 3. Wang Study: Comparison of YGTSS Scores in all Groups 
 
*significance reported at P < 0.05 
 
Table 4.  Wang Study: Clinical complications and side effects 
ADR Control (n=28) NDG (n=29 Hal (n=30) NDG + Hal (n=30) 
Sedation 1 (3.5%) 3 (10.3%)* 10 (33.3%) 12 (40.0%) 
Weight gain 2 (7.0%) 2 (6.9%) 4 (13.3%) 5 (16.7%) 
EPS 0 0* 5 (16.7%) 5 (16.7%) 
QT Prolongation 0 0* 5 (16.7%) 5 (16.7%) 
Nausea  0 3 (10.3%) 4 (13.3%) 4 (13.3%) 
Headache 0 1 (3.4%) 4 (13.3%) 6 (20.0%) 
Anxiety 1 (3.5%) 0* 6 (20.0%) 4 (13.3%) 
Increased Appetite 0 4 (13.8%) 4 (13.3%) 7 (23.3%) 
Note: * significance P<0.05 
 The Zhao study evaluated the efficacy and safety of Ningdong granule vs. placebo over 
an 8-week randomized, placebo controlled, double blind trial. 68 pediatric patients between the 
ages of 7-18 with TS were recruited in this study; 3 patients in the placebo group and 1 in the 
NDG group did not complete the full course of treatment and were excluded from analysis.  
Exclusion criteria included those who had IQ < 70, tic syndromes caused by other disease, 
persons with liver, kidney or any other organ dysfunction, and finally any applicant whose 
baseline was <10 on the YGTSS. Patients were randomly assigned to either a treatment group 
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(n=33) receiving NDG 1g/kg/day (36 g/day max) or the placebo group (n=31) and given starch 
formulated to be identical to NDG at the same frequency. The Ningdong granule used was lot 
No. 20051017, manufactured by the Pharmaceutical Department of the Provincial Hospital 
Affiliated to Shandong University. There was no significant difference between the groups for 
age, weight, gender, previous pharmacotherapy use or baseline YGTSS score (P>0.05).  Mean 
baseline YGTSS score for Treatment group was 23.00  7.34 and baseline for the placebo group 
was 22.42  6.42.  YGTSS scores were measured at baseline, 4 and 8 weeks.  At each interval 
after treatment was started, there was found to be a significant reduction in tic symptoms from 
baseline in the NDG treatment group compared to the placebo group, but most notably so at the 
end of eight weeks (P<0.001).  There was little change in mean total YGTSS score (22.42 6.42 
to 20.00  6.12) in the placebo group from baseline to the end of the study.  There were no 
serious drug reactions reported during the study in either test group, however in the NDG 
treatment group there were two patients who experienced a decreased appetite and one who 
experienced constipation compared with none in the placebo group.  Less than 10% of the 
treatment population experienced any type of ADR, which is minimal compared to the 
potentially serious side effects of traditional antipsychotics like haloperidol.2,3  This study had 
several limitations in that it was short term, single centered study and was assessed only by the 
decrease in YGTSS score. 
Table 5. Zhao Study: YGTSS total tic score change for NDG vs. placebo 
Group Case Mean Baseline YGTSS total tic score Mean week 8 YGTSS total tic score 
NDG Treatment 33 23.00  7.34 13.48  7.25 
Placebo Control  31 22.42  6.42 20.00  6.12 
Statistical significance  P>0.05 P<0.001 
 
Russell, Efficacy of Ningdong Granule 
 
  
10 
DISCUSSION 
 This systematic review assessed the efficacy and safety of the Chinese herbal 
supplement, Ningdong granule vs. traditional haloperidol treatment in reducing tic symptoms in 
pediatric Tourette syndrome patients. Currently, herbal remedies are not widely used to treat TS 
in the United States. The results of these three studies show that NDG is an effective alternative 
to haloperidol with a much lower adverse drug reaction profile. While some ADRs for NDG do 
exist, they are fewer and far less severe reactions as compared to haloperidol. Drug to drug 
interactions were not accounted for in any of the studies as current drug use or medication for 
other diseases were criteria for exclusion.   
There were several limitations noted with the studies reviewed.  First, insurance in the 
United States will not currently cover herbal remedies and the FDA does not regulate the 
production of herbal supplements.  This is a problem for this type of study in the U.S as well as 
for consistent production and dosing of the supplement long term.  While the Ningdong granules 
used were produced by licensed Chinese pharmaceutical companies and were proven to be 
consistent in each trial, there was variation in the ingredients used, concentrations of ingredients 
and the dose administered between the three studies. Also, powdered human placenta was used 
in the formulation of the granule in two studies, which is currently against U.S. FDA regulation.  
Second, the results and outcomes were measured in the short term only for two of the three 
studies.  The Li study also assessed efficacy and ADRs six months after the study but were not 
required to answer the question posed in this review.  Last, all studies used only one method, the 
Yale Global Tic Severity Scale, to assess effectiveness in reducing tics in the patient population. 
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CONCLUSION 
 Ningdong granule is a safe and effective alternative therapy to haloperidol in the relief of 
tic symptoms in pediatric aged patients diagnosed with Tourette Syndrome.  All three studies 
included showed significant evidence improvement in YGTSS scores and thus total tic 
symptoms while having significantly fewer adverse drug reactions.  Although these studies did 
not compare Ningdong to other off-label drugs used for the treatment of tics, NDG has been 
shown to be more effective and more safe than the traditional antipsychotics prescribed. Even 
with different amounts and small variation in ingredients between manufacturers.  
 While the Ningdong granules used were produced by licensed Chinese pharmaceutical 
companies and were proven to be consistent in each trial, there was variation in the ingredients 
used, concentrations of ingredients and the dose administered between the three studies. It would 
be beneficial to have a normalized ingredient profile for future studies so that results could be 
more easily replicated by future studies.  Future studies should be multi-centered comparing 
multiple drugs to NDG and assess over the long term while utilizing multiple assessment tools to 
measure improvement in tic symptoms and overall psychological well-being.  Tools such as 
Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOC), Children’s Depression 
Inventory (CDI), Clinical Global Impression (CGI-I) and the Multidimensional Anxiety Scale for 
Children (MASC) would be beneficial in a multi-centered, long term study.3 
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